课件：精神分裂症门诊病人健康转归临床观察研究.ppt

* These Hazard Ratios should be interpreted as follows ‘再普乐 patients are 2.8 times more likely to remit compared with 氟哌啶醇 patients’ Additional analysis “time to remission” p 1-8 (of 8) * numbers supplied by Teena from additional analysis * There are no estimates for median time to relapse, hence this is not included. The survival figure has been truncated at 3 (年) for aesthetic reasons, this has no impact on the median times. Patients lost to follow up are censored at their last known visit. 125 patients have been excluded because of no baseline visit date. 33 patients have been excluded because of no visit date (however with more time I can manually attribute the visit prior to the missing visit). 1 patient has been excluded because of an incorrect date (visit date is prior to baseline date). * Based on additional analysis “time to relapse”, p 1-7 of 7 These Hazard Ratios should be interpreted as follows ‘the 利培酮k of discontinuing baseline monotherapy was 3 times higher for 氟哌啶醇 patients compared with olz patients’. * This histogram is scaled as a probability density; the sum of the bar height x bar width will equal 1 * Unfortunately, there was insufficient time to apply more sophisticated modelling to the CGI scores, hence we have stuck with the Blue Gum output. More conclusive findings should be apparent once we are better able to use the existing data, so I have kept these brief. * Unfortunately, there was insufficient time to apply more sophisticated modelling to the CGI scores, hence we have stuck with the Blue Gum output. More conclusive findings should be apparent once we are better able to use the existing data, so I have kept these brief. * Unfortunately, there was insufficient time to apply more sophisticated modelling to the CGI scores, hence we have stuck with the Blue Gum output. More conclusive findings should be apparent once we are better able to use the existing data, so I have kept these brief. * * 3年后体重增加的情况 0.0 与基线时体重相比(公斤) 再普乐 利培酮